Positive CHMP vote likely for Clovis' PARP inhibitor
Clovis Oncology Inc. (NASDAQ:CLVS) said EMA's CHMP communicated a "positive trend vote" for an MAA for rucaparib (CO-338) to treat platinum-sensitive, BRCA-mutant advanced ovarian cancer. Clovis expects a formal vote on the MAA at CHMP's...
